We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Brain MRI Analysis Device Aids Early Diagnosis of Neurodegenerative Diseases

By MedImaging International staff writers
Posted on 13 Oct 2023
Image: VUNO Med-DeepBrain aids in neurodegenerative disease using MRI (Photo courtesy of VUNO)
Image: VUNO Med-DeepBrain aids in neurodegenerative disease using MRI (Photo courtesy of VUNO)

A cutting-edge medical tool uses deep learning to examine brain MRI scans, aiding medical professionals in diagnosing neurodegenerative diseases like Alzheimer's and vascular dementia.

VUNO Inc.’s (Seoul, Korea) VUNO Med-DeepBrain is an AI-based brain imaging analysis medical device that analyzes brain MRI by dividing the brain into more than 100 different areas. It then offers data on the level of atrophy in each of these regions, all within just one minute. This advanced tool is particularly useful for medical professionals in detecting dementia due to neurodegenerative conditions like Alzheimer's and vascular dementia.

A recent study has shown that VUNO Med-DeepBrain is also effective in diagnosing "subjective cognitive decline," a stage that precedes the manifestation of full-blown dementia symptoms. This finding implies that the technology could be instrumental in flagging individuals who are more likely to transition from minor cognitive issues to severe dementia. The device has gained approval from the U.S. Food and Drug Administration (FDA), marking it as VUNO Inc.'s first product to achieve such certification. Looking ahead, VUNO aims to expand its presence in the U.S. healthcare market through its American subsidiary and also seeks to collaborate with global pharmaceutical firms and other organizations.

“We expect VUNO Med-DeepBrain to be the cornerstone of our expansion into the U.S. market,” said VUNO Chief Executive Officer Lee Ye-ha. “With the recent advent of next-generation dementia treatments, there is a growing demand for early diagnosis, and we will strengthen our sales efforts to rapidly expand this product in the U.S. market and contribute to solving the problem of dementia.”

Related Links:
VUNO Inc. 

Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Ultrasound Table
Women’s Ultrasound EA Table
Pocket Fetal Doppler
CONTEC10C/CL
Breast Localization System
MAMMOREP LOOP

Channels

General/Advanced Imaging

view channel
Image: The study developed a marker based on the analysis of routine CT scans of gastric cancer patients treated at UNICAMP. Higher radiodensity values for adipose tissue are linked to a worse prognosis. In contrast, higher values for muscle are linked to a more favorable outcome (Photo courtesy of FCM-UNICAMP)

CT-Derived Biomarker Predicts Outcomes in Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.